Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Pang, Aiming  [Clear All Filters]
2019
Zhang S, Zhang P, Wang Z, Liu L, He Y, Jiang E, Wei J, Yang D, Zhang R, Zhai W, et al. Posaconazole oral suspension as salvage therapy for invasive fungal disease in patients with hematological diseases. Future Microbiol. 2019.
2021
Wang J, Wang Q, Zhang H, He Y, Huang Y, Zhang R, Wei J, Ma Q, Pang A, Yang D, et al. Moderate to severe marrow fibrosis as a more advanced risk factor for MDS and MDS-AML patients with excess of blasts receiving allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2021.
2022
Zhao F, Shi Y, Chen X, Zhang R, Pang A, Zhai W, Yang D, He Y, Feng S, Zhang P, et al. Higher Dose of CD34 cells Promotes Early Reconstitution of Natural Killer Cells and Is Associated with Better Outcomes After Unmanipulated Hematopoietic Stem Cell Transplantation for Myeloid Malignancies. Transplant Cell Ther. 2022.
Chen J, Pang A, Zhao Y, Liu L, Ma R, Wei J, Chen X, He Y, Yang D, Zhang R, et al. Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment and outcomes. Hematology. 2022;27(1):293-299.
2023
Guo W, Liu X, Wang M, Liu J, Cao Y, Zheng Y, Zhai W, Chen X, Zhang R, Ma Q, et al. Application of prophylactic or pre-emptive therapy after allogeneic transplantation for high-risk patients with t(8;21) acute myeloid leukemia. Hematology. 2023;28(1):2205739.
Chen X, Ma Y, Zhang R, Zhai W, Ma Q, Pang A, Yang D, Wei J, He Y, Song Z, et al. Application prospect of low-dose porcine anti-thymocyte globulin in HLA-matched sibling donor transplantation. Hematology. 2023;28(1):2212943.
Cao Y, Gong X, Feng Y, Wang M, Hu Y, Liu H, Liu X, Qi S, Ji Y, Liu F, et al. The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases. Am J Hematol. 2023.
Zheng X, Gao H, Lu N, Wang M, Zhang H, Zheng Y, Shen B, Cao Y, Chen X, Zhai W, et al. Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms. Ann Hematol. 2023.
Ruan Y, Bi H, Luo X, Pang A, Zhang P, Cui Y. Elevated plasma levels of specific antiplatelet glycoprotein autoantibodies in patients with primary Sjögren syndrome with thrombocytopenia. Clin Rheumatol. 2023.
Zhao Y, An S, Bi H, Luo X, Wang M, Pang A, Jiang E, Cao Y, Cui Y. Evaluation of Platelet Parameters in Patients With Secondary Failure of Platelet Recovery and Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation. Clin Appl Thromb Hemost. 2023;29:10760296231157741.
Chen X, Zheng X, Lu N, Zhang R, Zhai W, Ma Q, Pang A, Yang D, Wei J, He Y, et al. Explorations of post-gDLI low-dose cyclophosphamide for preventing severe aGVHD. Int Immunopharmacol. 2023;125(Pt A):111165.
Chen X, Ma Q, Pang A, Yang D, Liang C, Liu Q, Liu X, Zheng X, Jiang E, Han M, et al. Hematopoietic stem cell transplantation from an infected SARS-CoV2 haploidentical donor: A case report. IDCases. 2023;34:e01913.
Shen Y, Yang D, Zhang R, Chen X, Ma Q, Wei J, Zhai W, Pang A, He Y, Jiang E, et al. The outcome of acute leukemia patients with SET-NUP214 fusion after allogeneic stem cell transplantation. Front Oncol. 2023;13:1256043.
Lv M, Liu L, He Y, Yang D, Ma Q, Pang A, Zhai W, Wei J, Huang Y, Chen X, et al. Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease. Br J Haematol. 2023.
Cao Y, Zheng X, Zhang H, Wang M, Guo W, Chen X, Zhai W, Wei J, Yang D, Huang Y, et al. Refractory patients with favorable/intermediate-risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation. Hematol Oncol. 2023.
Huo Y, Wu L, Pang A, Li Q, Hong F, Zhu C, Yang Z, Dai W, Zheng Y, Meng Q, et al. Single-cell dissection of human hematopoietic reconstitution after allogeneic hematopoietic stem cell transplantation. Sci Immunol. 2023;8(81):eabn6429.
Chen S, An L, Han J, Zheng X, Zhang X, Li G, Zhang Y, Cao W, Lv M, Yang D, et al. Successful Blinatumomab treatment in an allogeneic hematopoietic stem cell transplant recipient with EBV-related post-transplant lymphoproliferative disorder: A case report and literature review. Transpl Immunol. 2023:101895.
2024
Cao Y, Wang M, Wang F, Guo W, Ma Y, Li X, He Y, Pang A, Zhang R, Zhai W, et al. Decitabine in combination with idarubicin within a modified busulfan/cyclophosphamide conditioning regimen for patients with advanced myelodysplastic syndrome: A prospective multicenter clinical cohort study. Chin Med J (Engl). 2024.
Li J, Liu Y, Wang J, Wang Y, Pang A, Yang D, Chen X, Zhang R, Wei J, Ma Q, et al. Exploring strategies to optimise outcomes in hepatitis-associated aplastic anaemia patients following haematopoietic stem cell transplantation. Sci Rep. 2024;14(1):5178.
An S, Bi H, Luo X, Zhu C, Wang M, Pang A, Cui Y. Identification of key genes of diabetic cardiomyopathy in hiPSCs-CMs based on bioinformatics analysis. Mol Cell Biochem. 2024.
Zhang H, Zheng X, Guo W, Xia Y, Zhang R, Zhai W, Chen X, Ma Q, Yang D, Wei J, et al. Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system. Exp Hematol Oncol. 2024;13(1):16.
Gao H, Wang J, Zheng X, Pei X, Zheng Y, Zhai W, Zhang R, Chen X, Ma Q, Wei J, et al. Ursodeoxycholic acid does not reduce SARS-CoV-2 infection in newly allogeneic hematopoietic stem cell transplantation recipients: a prospective NICHE cohort. Front Cell Infect Microbiol. 2024;14:1324019.